Literature DB >> 23143553

Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.

Yuechi Sun1, Yuan Liu, Bing Yan, Guixiu Shi.   

Abstract

To study the clinical features and associated risk factors of interstitial lung disease (ILD) in clinically amyopathic dermatomyositis (CADM) in Chinese patients. Forty-one Chinese Han patients with a diagnosis of CADM in West China Hospital from August 2008 to 2011 were retrospectively analyzed. The prevalence of ILD in CADM patients is 60.98 %, in which 26.83 % for acute/subacute interstitial pneumonia (A/SIP) and 34.15 % for chronic interstitial pneumonia (CIP). Mortality of A/SIP is 63.64 %, with a 6-month survival rate of 54.50 %. Levels of erythrocyte sedimentation rate, serum ferritin, alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, hydroxybutyric dehydrogenase, and immunoglobulin A (IgA) are higher in CADM-ILD patients than CADM patients without ILD. Levels of serum ALB and lymphocyte count in peripheral blood are significant lower in A/SIP than in CIP group. Sign of ground glass opacities in high-resolution computed tomography (HRCT) images is more common in A/SIP group, and diffusion function is worse in these patients compared with CIP group. The prevalence of ILD in Chinese CADM patients is strikingly high, and A/SIP is a major cause of death in CADM patients. Laboratory findings combined with HRCT examination and pulmonary function tests can provide valuable predictive information of ILD or A/SIP in CADM patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143553     DOI: 10.1007/s00296-012-2545-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

3.  Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement.

Authors:  J M Grau; O Miró; E Pedrol; J Casademont; F Masanés; C Herrero; G Haussman; A Urbano-Márquez
Journal:  J Rheumatol       Date:  1996-11       Impact factor: 4.666

4.  Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Masako Hara; Ikuko Masuda; Yasuhiro Katsumata; Mikiko Shinozaki; Yuko Ota; Eri Ozeki; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-04-12       Impact factor: 7.580

5.  Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine.

Authors:  Y Nawata; K Kurasawa; K Takabayashi; S Miike; N Watanabe; M Hiraguri; Y Kita; M Kawai; Y Saito; I Iwamoto
Journal:  J Rheumatol       Date:  1999-07       Impact factor: 4.666

6.  Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.

Authors:  E H Kang; E B Lee; K C Shin; C H Im; D H Chung; S K Han; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

7.  Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases.

Authors:  Gen Ideura; Masayuki Hanaoka; Tomonobu Koizumi; Keisaku Fujimoto; Yasuhiro Shimojima; Wataru Ishii; Masayuki Matsuda; Shuichi Ikeda
Journal:  Respir Med       Date:  2007-03-13       Impact factor: 3.415

8.  Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.

Authors:  Margo J Bendewald; David A Wetter; Xujian Li; Mark D P Davis
Journal:  Arch Dermatol       Date:  2010-01

Review 9.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  18 in total

Review 1.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Authors:  Roberta Vilela Lopes Koyama; Tiago Kiyoshi Kitabayashi Braga; George Alberto da Silva Dias; Satomi Fujihara; Hellen Thais Fuzii; Gilberto Toshimitsu Yoshikawa
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

2.  Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.

Authors:  Qianqian Wang; Congcong Gao; Chunyi Zhang; Menghui Yao; Wenfang Liang; Wenbo Sun; Zhaohui Zheng
Journal:  Clin Rheumatol       Date:  2022-02-09       Impact factor: 2.980

Review 3.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

4.  Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.

Authors:  Satoshi Ikeda; Machiko Arita; Kenta Misaki; Shohei Mishima; Takuya Takaiwa; Akihiro Nishiyama; Akihiro Ito; Kenjiro Furuta; Toshihide Yokoyama; Fumiaki Tokioka; Maki Noyama; Hiroshige Yoshioka; Tadashi Ishida
Journal:  Springerplus       Date:  2015-05-28

5.  Prognostic factors for myositis-associated interstitial lung disease.

Authors:  Tomoyuki Fujisawa; Hironao Hozumi; Masato Kono; Noriyuki Enomoto; Dai Hashimoto; Yutaro Nakamura; Naoki Inui; Koshi Yokomura; Naoki Koshimizu; Mikio Toyoshima; Toshihiro Shirai; Kazumasa Yasuda; Hiroshi Hayakawa; Takafumi Suda
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 6.  Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Guoqin Wu; Di Gao; Guijian Liu; Lin Pan; Liyan Ni; Zheng Li; Qiang Wang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

7.  Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

Authors:  Satoshi Ikeda; Machiko Arita; Mitsunori Morita; Satoshi Ikeo; Akihiro Ito; Fumiaki Tokioka; Maki Noyama; Kenta Misaki; Kenji Notohara; Tadashi Ishida
Journal:  BMC Pulm Med       Date:  2015-12-09       Impact factor: 3.317

8.  Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis.

Authors:  Jeong Uk Lim; Hye Seon Kang; Yong Hyun Kim; Tae Jung Kim
Journal:  Balkan Med J       Date:  2017-04-13       Impact factor: 2.021

9.  Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.

Authors:  Dong Jin Go; Eun Young Lee; Eun Bong Lee; Yeong Wook Song; Maximilian Ferdinand Konig; Jin Kyun Park
Journal:  J Korean Med Sci       Date:  2016-02-04       Impact factor: 2.153

Review 10.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.